PD-1/PD-L1抑制剂治疗肺癌的不良反应与中医药干预的研究现状

doi:10.3969/j.issn.1006-6233.2022.06.037

摘要
图/表
参考文献
相关文章 (15)

[1] Wild CP,Weiderpass E,Stewart BW.2020 world cancer report:cancer reseach for cancer prevention[M].Lyon,France:International Agency for Research on Cancer,2020.
[2] Baraibar I,Melero I,Ponz-Sarvise M,et al.Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer[J]. Drug Saf,2019,42(2):281-294.
[3] 张露露.下调肿瘤细胞PD-L1表达的中药单体的筛选及其对T细胞肿瘤杀伤促进作用的研究[D].北京:中国中医科学院,2020.
[4] 周彩存,王洁,步宏,等.中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版)[J].中国肺癌杂志,2020,23(2):65-76.
[5] Wang YC, Zhou SH,Yang F,et al.Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials:a systematic review and meta-analysis[J].JAMA Oncol,2019,5(7):1008-1019.
[6] Pai-Scherf L,Blumenthal GM,Li H,et al.FDA approval summary:pembrolizumab for treatment of metastatic non-small cell lung cancer:first-line therapy and beyond[J].Oncologist,2017,22(11):1392-1399.
[7] Shen L,Guo J,Zhang QY,et al.Tislelizumab in Chinese patients with advanced solid tumors:an open-label,non-comparative,phase 1/2 study[J].Immunother Cancer, 2020,8(1):e000437.
[8] Malhotra J,Jabbour SK,Aisner J.Current state of immunotherapy for non-small cell lung cancer[J].Transl Lung Cancer Res,2017,6(5):612.
[9] Garassino MC,Cho BC,Kim JH,et al.Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC):an open-label,single-arm,phase 2 study[J].Lancet Oncol,2018,19(4):521-536.
[10] 白日兰,崔久嵬.免疫检查点抑制剂治疗相关不良反应-新探索、新挑战[J].中国肿瘤生物治疗杂志,2021,28(5):419-430.
[11] Arbour KC,Mezquita L,Long N,et al.Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer[J].Clin Oncol,2018,(36):2872-2878.
[12] 陈泓志,梁伟林,顾瞻,等.程序性细胞死亡蛋白-1及其配体抑制剂免疫相关不良反应的中医病因病机及治法[J].世界中医药,2021,16(9):1386-1390,1399.
[13] 谭炜焓,金钊,王倩,等.PD-1/PD-L1抑制剂的中药性能探讨[J].新中医,2020,52(12):206-208.
[14] Garon EB,Hellmann MD,Rizvi NA,et al.Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab:results from the phase I KEYNOTE-001 study[J].Clin Oncol,2019,37(28):JCO.19.00934.
[15] 熊溢,张明军.保肝护肝中药及其产品研发的现状与展望[J].中兽医医药杂志,2019,38(5):98-102.
[16] 林昱.中药泻火解毒汤治疗大叶性肺炎疗效观察[J].中国中西医结合儿科学,2016,8(1):67-69.